Singapore Ulcerative colitis is an inflammatory bowel disease that
affects the colon and rectum of the human body. The disease affects people of
any age and most commonly it begins during adolescence and early adulthood, but
it may also occur later in life. Ulcerative colitis is highly prevalent in the
U.S., England, and northern Europe. The most commonly preferred treatment
options for ulcerative colitis are traditional medications made of biologics
and small molecules.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝
𝐒𝐚𝐦𝐩𝐥𝐞
𝐑𝐞𝐩𝐨𝐫𝐭
https://www.alliedmarketresearch.com/request-sample/3965
Factor that drives Singapore ulcerative colitis market growth
include increase in number of inflammatory bowel disease. In addition, rise in
number of ulcerative colitis incidences propels growth of the market. However,
rise in burden of inflammatory bowel disease increases growth of the
market. Furthermore, the Food and Drug
Administration (FDA) aims to enhance availability of reliable and effective
drugs to meet public health needs and increase access to treat consumers.
Moreover, rise in development of pharmaceutical and medical
device industries and improvement in healthcare spending are anticipated to
drive growth of the ulcerative colitis market. In addition, increase in
development of new product launches led to rise in the healthcare sector,
thereby propelling growth of the market.
Moreover, governments initiatives for development of new
drugs and healthcare sector for manufacturing of ulcerative colitis drugs are
the key factors that boost growth of the market.
For instance, in May 2018, Takeda Pharmaceutical Company
Ltd. and Shire Plc. announced that Takeda had reached an agreement on the terms
of proposed offer to acquire all of
outstanding shares and future common shares of Shire Plc. In addition,
in June 2019, Abbvie completed the acquisition of Allergan to expand its
product portfolio to offer extensively advanced treatments for patients.
Allergan launched a monoclonal antibody called brazikumab, which is used in the
treatment of ulcerative colitis. Thus, increase in development of new drugs
drives the substantial growth of the ulcerative colitis market size during
forecast period.
By molecule type, the market is divided into small molecules
and biologics. The small molecule segment acquired top position in the
ulcerative colitis industry in 2020, and this trend is expected to continue
during the forecast period, owing to large number of drugs offered by key
players and increase in use of drugs for the treatment of inflammatory
gastrointestinal disorder. By route of administration, the market is fragmented
into oral and injectables.
𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱
𝐑𝐞𝐩𝐨𝐫𝐭
https://www.alliedmarketresearch.com/ulcerative-colitis-market
0 Comments